Baidu
map

快来看!这些药品和疫苗的注册申请拟纳入优先审评程序啦!

2018-04-30 佚名 国家食品药品监督管理总局药品审评中心

国家食品药品监督管理总局药品审评中心2018年4月23日发布“拟纳入优先审评程序药品注册申请的公示(第二十八批)”

国家食品药品监督管理总局药品审评中心2018年4月23日发布“拟纳入优先审评程序药品注册申请的公示(第二十八批)”

消息原文如下:

根据总局《关于鼓励药品创新实行优先审评审批的意见》(食药监药化管〔2017〕126号),我中心组织专家对申请优先审评的药品注册申请进行了审核论证,现将拟优先审评的药品注册申请及其申请人予以公示,公示期5日。公示期间如有异议,请在我中心网站“信息公开-->优先审评公示-->拟优先审评品种公示”栏目下提出异议。

在本次公示中,小编将您关注的抗肿瘤药物、免疫抑制剂,以及目前热议的人乳头瘤状病毒(HPV)疫苗的公示内容,暂列如下:



以上信息,供读者参考

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1634762, encodeId=c9491634e62a3, content=<a href='/topic/show?id=6da725e314e' target=_blank style='color:#2F92EE;'>#优先审评#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25731, encryptionId=6da725e314e, topicName=优先审评)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4be222283241, createdName=ms5822920152752585, createdTime=Thu Aug 30 23:37:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556814, encodeId=54b715568149c, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Wed May 02 13:37:00 CST 2018, time=2018-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310799, encodeId=6dad310e99ec, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Mon Apr 30 23:04:48 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310788, encodeId=1965310e88e5, content=对于初学者非常好.学习了.谢谢老师, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Mon Apr 30 22:42:32 CST 2018, time=2018-04-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1634762, encodeId=c9491634e62a3, content=<a href='/topic/show?id=6da725e314e' target=_blank style='color:#2F92EE;'>#优先审评#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25731, encryptionId=6da725e314e, topicName=优先审评)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4be222283241, createdName=ms5822920152752585, createdTime=Thu Aug 30 23:37:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556814, encodeId=54b715568149c, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Wed May 02 13:37:00 CST 2018, time=2018-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310799, encodeId=6dad310e99ec, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Mon Apr 30 23:04:48 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310788, encodeId=1965310e88e5, content=对于初学者非常好.学习了.谢谢老师, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Mon Apr 30 22:42:32 CST 2018, time=2018-04-30, status=1, ipAttribution=)]
    2018-05-02 zhyy93
  3. [GetPortalCommentsPageByObjectIdResponse(id=1634762, encodeId=c9491634e62a3, content=<a href='/topic/show?id=6da725e314e' target=_blank style='color:#2F92EE;'>#优先审评#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25731, encryptionId=6da725e314e, topicName=优先审评)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4be222283241, createdName=ms5822920152752585, createdTime=Thu Aug 30 23:37:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556814, encodeId=54b715568149c, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Wed May 02 13:37:00 CST 2018, time=2018-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310799, encodeId=6dad310e99ec, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Mon Apr 30 23:04:48 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310788, encodeId=1965310e88e5, content=对于初学者非常好.学习了.谢谢老师, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Mon Apr 30 22:42:32 CST 2018, time=2018-04-30, status=1, ipAttribution=)]
    2018-04-30 131****2916

    不错的文章值得推荐

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1634762, encodeId=c9491634e62a3, content=<a href='/topic/show?id=6da725e314e' target=_blank style='color:#2F92EE;'>#优先审评#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25731, encryptionId=6da725e314e, topicName=优先审评)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4be222283241, createdName=ms5822920152752585, createdTime=Thu Aug 30 23:37:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556814, encodeId=54b715568149c, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Wed May 02 13:37:00 CST 2018, time=2018-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310799, encodeId=6dad310e99ec, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Mon Apr 30 23:04:48 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310788, encodeId=1965310e88e5, content=对于初学者非常好.学习了.谢谢老师, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Mon Apr 30 22:42:32 CST 2018, time=2018-04-30, status=1, ipAttribution=)]
    2018-04-30 虈亣靌

    对于初学者非常好.学习了.谢谢老师

    0

相关资讯

从“一致性评价”和“优先审评”中寻医药股机会

医药行业整体估值喜忧参半,目前水平大约在36倍左右,同比下降,可能是受到诸多省份对抗菌药物、中药注射剂、辅助性药品、营养性药品等药品的限用、停用的影响。2018年,随着一些公司提前通过仿制药一致性评价和新药申报进入优先审评,预计行业估值会得到一定提升,大概保持在10%左右的增长。

诺华ceritinib获FDA优先审评,有望一线用于肺癌治疗

今日,诺华(Novartis)宣布,美国FDA接受了该公司的补充新药申请(sNDA),并批准优先审评扩大使用Zykadia(ceritinib)一线治疗转移性非小细胞肺癌(NSCLC)患者,这些病人的肿瘤通过FDA批准的测试所检测为间变性淋巴瘤激酶阳性(ALK+)。 FDA还向Zykadia授予了突破性疗法认定,用于一线治疗ALK+转移性NSCLC患者,癌细胞转移至了脑部。在全世界范围内,肺癌导致

第27批拟被纳入优先审评药品名单出炉 26药品入选

CDE官网公示了第二十七批拟纳入优先审评程序药品注册申请名单,其中,12药品为新药上市,9药品为新药临床,其余5药品为仿制药上市申请。

抗疟疾新药获FDA优先审评资格

近日,60 Degrees Pharmaceuticals(60P)宣布,美国FDA授予其预防成人疟疾药物Tafenoquine (TQ)优先审评资格。2018年1月,该药物获得FDA的快速通道资格。

Baidu
map
Baidu
map
Baidu
map